Literature DB >> 6897022

Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors.

D S Fulton, V A Levin, P H Gutin, M S Edwards, M L Seager, J Stewart, C B Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6897022     DOI： 10.1007/bf00254052

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  16 in total

1.  CENTRAL NERVOUS SYSTEM INVOLVEMENT BY LEUKEMIA IN CHILDREN. II. THERAPY WITH INTRATHECAL METHOTREXATE.

Authors:  C B HYMAN; J M BOGLE; C A BRUBAKER; K WILLIAMS; D HAMMOND
Journal:  Blood       Date:  1965-01       Impact factor: 22.113

2.  CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.

Authors:  J L Nugent; P A Bunn; M J Matthews; D C Ihde; M H Cohen; A Gazdar; J D Minna
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

3.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

4.  Current status of intrathecal chemotherapy for human meningeal neoplasms.

Authors:  W A Bleyer
Journal:  Natl Cancer Inst Monogr       Date:  1977-12

5.  Intrathecal arabinosyl cytosine in meningeal leukemia.

Authors:  J J Wang; C B Pratt
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

6.  Treatment of central nervous system leukemia with intrathecal cytosine arabinoside.

Authors:  P R Band; J F Holland; J Bernard; M Weil; M Walker; D Rall
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

7.  Proliferative kinetics of central nervous system (CNS) leukemia.

Authors:  A H Kuo; X Yataganas; J H Galicich; J Fried; B D Clarkson
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

8.  Cerebrospinal fluid polyamines in patients with Glioblastoma multiforme and anaplastic astrocytoma.

Authors:  D S Fulton; V A Levin; W P Lubich; C B Wilson; L J Marton
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

9.  The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A).

Authors:  A E Evans; E S Gilbert; R Zandstra
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

10.  Heuristic modeling of drug delivery to malignant brain tumors.

Authors:  V A Levin; C S Patlak; H D Landahl
Journal:  J Pharmacokinet Biopharm       Date:  1980-06
View more
  18 in total

Review 1.  Current options for the treatment of neoplastic meningitis.

Authors:  Ilkcan Cokgor; Allan H Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

2.  Lipid association increases the potency against primary medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats.

Authors:  C Bethune; A Blum; J R Geyer; J R Silber; R J Ho
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  Extensive spinal necrosis with spinal leptomeningeal dissemination of cerebral astrocytoma. Case report.

Authors:  T Yamaki; M Otaki; T Uede; J Niwa; K Hashi; T Uede; K Kikuchi
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

4.  Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia.

Authors:  V A Levin; M Chamberlain; P Silver; L Rodriguez; M Prados
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs.

Authors:  M Kochi; S Takaki; J Kuratsu; H Seto; I Kitamura; Y Ushio
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rats.

Authors:  T Y Huang; N Arita; Y Ushio; T Hayakawa; K Yamada
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.

Authors:  J S Driscoll; D G Johns; J Plowman
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine.

Authors:  P Lafolie; J Liliemark; O Björk; J Aman; L Wranne; C Peterson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

9.  Ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)-methyl]-1-(2-chloroethyl-1-nitrosou rea hydrochloride for subarachnoid dissemination of gliomas.

Authors:  Y Ushio; M Kochi; I Kitamura; J Kuratsu
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

10.  Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.

Authors:  I Slavc; E Schuller; T Czech; J A Hainfellner; R Seidl; K Dieckmann
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.